Compare MCD & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCD | MRK |
|---|---|---|
| Founded | 1940 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6B | 317.8B |
| IPO Year | 1997 | 1995 |
| Metric | MCD | MRK |
|---|---|---|
| Price | $272.54 | $150.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 17 |
| Target Price | ★ $344.17 | $125.59 |
| AVG Volume (30 Days) | 4.2M | ★ 7.8M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | 2.56% | ★ 3.06% |
| EPS Growth | 4.92 | ★ 8.01 |
| EPS | ★ 6.10 | N/A |
| Revenue | $26,885,000,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $7.65 | $3.61 |
| Revenue Next Year | $6.00 | $5.41 |
| P/E Ratio | $44.51 | ★ N/A |
| Revenue Growth | ★ 3.72 | 1.31 |
| 52 Week Low | $260.96 | $77.58 |
| 52 Week High | $341.75 | $154.49 |
| Indicator | MCD | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 73.39 |
| Support Level | $271.91 | $113.32 |
| Resistance Level | $278.54 | N/A |
| Average True Range (ATR) | 4.78 | 3.69 |
| MACD | 0.08 | 2.03 |
| Stochastic Oscillator | 53.74 | 85.78 |
McDonald's is the world's largest restaurant brand, with nearly $139 billion in systemwide sales across more than 45,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 62%), with the remainder stemming from company-operated restaurants across three segments: the United States (39% of systemwide sales), international operated markets (35%), and international developmental/licensed markets (26%).
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).